Cargando…
Molecular Pathways of Diabetic Kidney Disease Inferred from Proteomics
Diabetic kidney disease (DKD) affects an estimated 20–40% of type 2 diabetes patients and is among the most prevalent microvascular complications in this patient population, contributing to high morbidity and mortality rates. Currently, changes in albuminuria status are thought to be a primary indic...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9842482/ https://www.ncbi.nlm.nih.gov/pubmed/36760602 http://dx.doi.org/10.2147/DMSO.S392888 |
_version_ | 1784870135807344640 |
---|---|
author | Wei, Lan Han, Yuanyuan Tu, Chao |
author_facet | Wei, Lan Han, Yuanyuan Tu, Chao |
author_sort | Wei, Lan |
collection | PubMed |
description | Diabetic kidney disease (DKD) affects an estimated 20–40% of type 2 diabetes patients and is among the most prevalent microvascular complications in this patient population, contributing to high morbidity and mortality rates. Currently, changes in albuminuria status are thought to be a primary indicator of the onset or progression of DKD, yet progressive nephropathy and renal impairment can occur in certain diabetic individuals who exhibit normal urinary albumin levels, emphasizing the lack of sensitivity and specificity associated with the use of albuminuria as a biomarker for detecting diabetic kidney disease and predicting DKD risk. According to the study, a non-invasive method for early detection or prediction of DKD may involve combining proteomic analytical techniques such second generation sequencing, mass spectrometry, two-dimensional gel electrophoresis, and other advanced system biology algorithms. Another category of proteins of relevance may now be provided by renal tissue biomarkers. The establishment of reliable proteomic biomarkers of DKD represents a novel approach to improving the diagnosis, prognostic evaluation, and treatment of affected patients. In the present review, a series of protein biomarkers that have been characterized to date are discussed, offering a theoretical foundation for future efforts to aid patients suffering from this debilitating microvascular complication. |
format | Online Article Text |
id | pubmed-9842482 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-98424822023-02-08 Molecular Pathways of Diabetic Kidney Disease Inferred from Proteomics Wei, Lan Han, Yuanyuan Tu, Chao Diabetes Metab Syndr Obes Review Diabetic kidney disease (DKD) affects an estimated 20–40% of type 2 diabetes patients and is among the most prevalent microvascular complications in this patient population, contributing to high morbidity and mortality rates. Currently, changes in albuminuria status are thought to be a primary indicator of the onset or progression of DKD, yet progressive nephropathy and renal impairment can occur in certain diabetic individuals who exhibit normal urinary albumin levels, emphasizing the lack of sensitivity and specificity associated with the use of albuminuria as a biomarker for detecting diabetic kidney disease and predicting DKD risk. According to the study, a non-invasive method for early detection or prediction of DKD may involve combining proteomic analytical techniques such second generation sequencing, mass spectrometry, two-dimensional gel electrophoresis, and other advanced system biology algorithms. Another category of proteins of relevance may now be provided by renal tissue biomarkers. The establishment of reliable proteomic biomarkers of DKD represents a novel approach to improving the diagnosis, prognostic evaluation, and treatment of affected patients. In the present review, a series of protein biomarkers that have been characterized to date are discussed, offering a theoretical foundation for future efforts to aid patients suffering from this debilitating microvascular complication. Dove 2023-01-12 /pmc/articles/PMC9842482/ /pubmed/36760602 http://dx.doi.org/10.2147/DMSO.S392888 Text en © 2023 Wei et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Wei, Lan Han, Yuanyuan Tu, Chao Molecular Pathways of Diabetic Kidney Disease Inferred from Proteomics |
title | Molecular Pathways of Diabetic Kidney Disease Inferred from Proteomics |
title_full | Molecular Pathways of Diabetic Kidney Disease Inferred from Proteomics |
title_fullStr | Molecular Pathways of Diabetic Kidney Disease Inferred from Proteomics |
title_full_unstemmed | Molecular Pathways of Diabetic Kidney Disease Inferred from Proteomics |
title_short | Molecular Pathways of Diabetic Kidney Disease Inferred from Proteomics |
title_sort | molecular pathways of diabetic kidney disease inferred from proteomics |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9842482/ https://www.ncbi.nlm.nih.gov/pubmed/36760602 http://dx.doi.org/10.2147/DMSO.S392888 |
work_keys_str_mv | AT weilan molecularpathwaysofdiabetickidneydiseaseinferredfromproteomics AT hanyuanyuan molecularpathwaysofdiabetickidneydiseaseinferredfromproteomics AT tuchao molecularpathwaysofdiabetickidneydiseaseinferredfromproteomics |